ArticleBMC psychiatry2026
Plasma chromogranin a levels and their role in the etiology of anxiety disorders in children and adolescents.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnxiety disorder is a common psychiatric condition in pediatric populations that may become chronic and impair functioning if left untreated. Chromogranin A (CgA) is a polypeptide co-secreted with catecholamines in response to stress and anxiety. The association between CgA and anxiety disorder has been investigated in adult populations; however, data in children and adolescents remain limited. This research sets out to analyze, for the first time, plasma CgA concentrations in medication-naïve children and adolescents diagnosed with anxiety disorders and to contrast these findings with data obtained from a control group.
methodsThis cross-sectional study included 37 medication-naïve children and adolescents aged 9-18 years diagnosed with anxiety disorders and 34 controls with similar age and sex distributions. Plasma chromogranin A (CgA) concentrations were measured using an enzyme-linked immunosorbent assay (ELISA) and compared between the groups. The parents of all participants competed the SCARED Parent Form.
resultsTotal and subscale SCARED scores were significantly higher in the anxiety disorder group compared with controls (all p < 0.001). Plasma CgA levels exhibited no significant intergroup variation between AD and control groups (p > 0,05). Correlation analyses revealed no significant associations between plasma CgA levels and SCARED total or subscale scores (all p > 0.05). Among sociodemographic variables, only family structure differed significantly between the groups (p = 0.012).
conclusionsIn pediatric populations, no significant difference in plasma CgA levels was observed between anxiety disorder and control groups, in contrast to findings in adult studies. This discrepancy may be related to developmental factors such as autonomic nervous system maturation and hormonal changes. Further studies are needed to clarify the role of CgA in the pathophysiology of anxiety disorders in children and adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.